Project Grant K08HL184051
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $150K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Forest Hills, TN 37215, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University $577,334 on July 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a sensory airway stent for continuous monitoring of airway conditions. The recipient is creating a sensor-integrated airway stent (SAS) equipped with flexible sensors and a wearable magnetic actuation unit designed to monitor stent patency and airway health in the central airway. The innovation addresses central airway...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $917,304 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular and molecular coordination of alveolar regeneration. The award supports research into how epithelial, endothelial, and mesenchymal cells coordinate repair of alveolar structures damaged by infection, environmental toxins, hyperoxia, or barotrauma. The project examines...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Vanderbilt University Medical Center $341,280 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year mentored career development project investigating apoptosis resistance mechanisms in pulmonary arterial smooth muscle cells. Dr. Niedermeyer, under mentorship from Dr. Larissa Shimoda and Dr. Mahendra Damarla, will conduct hands-on laboratory research, complete...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart, Lung, and Blood Institute awarded ST Jude Children's Research Hospital Inc. $150,104 on March 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate influenza-induced lung damage and hypoxemia. The research project, "Decoding Influenza-Induced Damage: What's All the Hyp(oxia) About?," uses damage-responsive fibroblasts (DRFibs) and ADAMTS4-knockout mice to elucidate how preventing T cell and fibroblast communication affects T cell...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $126,518 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to build a patient-oriented research mentoring program in human neonatal and infant airway biology. The award funds mentoring and research addressing mechanisms regulating airway epithelial immune responses in early life, with particular focus on populations historically excluded from respiratory research: infants with...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $471,280 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate in silico and in vitro modeling platforms for comparing surgical repair strategies in atrioventricular septal defects (AVSD). The research will create matched computational and laboratory-based functional models of atrioventricular valves from AVSD patients to identify optimal surgical...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $1,741,543 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate lung injury in pediatric hematopoietic cell transplant recipients. The research examines molecular mechanisms of pulmonary toxicity in pediatric HCT recipients, who experience lung injury in up to 40% of cases with mortality rates of 40% when requiring...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $2.591 million on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of LRRC8 anion channels in sepsis-induced vascular dysfunction. The award funds research examining how superoxide influx through leucine-rich repeat containing 8A (LRRC8A) and LRRC8C channels contributes to vascular inflammation and dysfunction during sepsis. The research tests the...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...